195
Participants
Start Date
March 23, 2009
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
Natalizumab
Participants treated with Tysabri
Research Site, Graz
Research Site, Innsbruck
Research Site, Salzburg
Research Site, Vienna
Research Site, Villach
Research Site, Aarhus
Research Site, Copenhagen
Research Site, Odense
Research Site, Bergen
Research Site, Bodø
Research Site, Drammen
Research Site, Førde
Research Site, Lillehammer
Research Site, Molde
Research Site, Oslo
Research Site, Danderyd
Research Site, Gothenburg
Research Site, Helsingborg
Research Site, Jönköping
Research Site, Karlstad
Research Site, Lund
Research Site, Malmo
Research Site, Norrköping
Research Site, Örebro
Research Site, Stockholm
Research Site, Trollhättan
Research Site, Umeå
Lead Sponsor
Biogen
INDUSTRY